Zürcher Nachrichten - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.184217
AFN 71.778596
ALL 94.26058
AMD 418.558169
ANG 2.039871
AOA 1044.771654
ARS 1684.037898
AUD 1.652409
AWG 2.052229
AZN 1.941395
BAM 1.955605
BBD 2.29677
BDT 140.265982
BGN 1.926481
BHD 0.429957
BIF 3386.861518
BMD 1.139336
BND 1.475553
BOB 7.880212
BRL 5.89839
BSD 1.140386
BTN 107.036303
BWP 15.497451
BYN 3.307369
BYR 22330.988246
BZD 2.293471
CAD 1.616661
CDF 2583.449152
CHF 0.922605
CLF 0.026705
CLP 1051.03496
CNY 7.745378
CNH 7.752824
COP 3917.408495
CRC 517.748256
CUC 1.139336
CUP 30.192408
CVE 110.253981
CZK 24.27816
DJF 203.069705
DKK 7.480658
DOP 67.003304
DZD 152.015808
EGP 56.43136
ERN 17.090042
ETB 183.850126
FJD 2.581854
FKP 0.861788
GBP 0.863297
GEL 3.01359
GGP 0.861788
GHS 12.857715
GIP 0.861788
GMD 83.171943
GNF 9992.001402
GTQ 8.700131
GYD 238.656149
HKD 8.935301
HNL 30.511951
HRK 7.539903
HTG 149.045104
HUF 354.163079
IDR 20349.226973
ILS 3.420345
IMP 0.861788
INR 107.508332
IQD 1493.850705
IRR 1566872.020062
ISK 144.115067
JEP 0.861788
JMD 179.602051
JOD 0.807834
JPY 184.293362
KES 147.565252
KGS 99.635383
KHR 4577.542521
KMF 494.472282
KPW 1025.40292
KRW 1749.029518
KWD 0.35275
KYD 0.950305
KZT 553.304703
LAK 25030.498458
LBP 102119.294221
LKR 383.321691
LRD 207.719241
LSL 18.745127
LTL 3.364164
LVL 0.689173
LYD 7.320268
MAD 10.693231
MDL 20.218979
MGA 4823.517939
MKD 61.628841
MMK 2391.906346
MNT 4077.580531
MOP 9.211779
MRU 45.511452
MUR 53.834064
MVR 17.603174
MWK 1977.402379
MXN 19.943172
MYR 4.65765
MZN 72.807828
NAD 18.745127
NGN 1567.875065
NIO 41.965806
NOK 11.31707
NPR 171.257885
NZD 2.016346
OMR 0.438256
PAB 1.140386
PEN 3.888611
PGK 5.0045
PHP 69.855021
PKR 317.362483
PLN 4.291823
PYG 6960.304389
QAR 4.156785
RON 5.244483
RSD 117.36827
RUB 88.591146
RWF 1670.033097
SAR 4.282472
SBD 9.173881
SCR 16.016599
SDG 683.602068
SEK 11.094411
SGD 1.474533
SHP 0.850629
SLE 28.259714
SLL 23891.313258
SOS 651.734866
SRD 42.70578
STD 23581.957684
STN 24.497552
SVC 9.978003
SYP 125.933213
SZL 18.734128
THB 38.028805
TJS 10.554045
TMT 3.987676
TND 3.379962
TOP 2.743248
TRY 53.039861
TTD 7.750225
TWD 36.299026
TZS 2999.100271
UAH 51.186584
UGX 4185.581694
USD 1.139336
UYU 45.775425
UZS 13697.631062
VES 707.246307
VND 29964.540351
VUV 136.297015
WST 3.167398
XAF 655.89145
XAG 0.019435
XAU 0.00028
XCD 3.079113
XCG 2.055195
XDR 0.815718
XOF 655.89145
XPF 119.331742
YER 271.874128
ZAR 19.354809
ZMK 10255.396502
ZMW 20.541947
ZWL 366.865771
  • CMSC

    -0.1160

    21.93

    -0.53%

  • BCE

    -0.2800

    22.92

    -1.22%

  • CMSD

    -0.1600

    21.77

    -0.73%

  • BCC

    1.2600

    81.02

    +1.56%

  • RBGPF

    3.7000

    65

    +5.69%

  • RIO

    -1.3700

    93.74

    -1.46%

  • GSK

    0.6100

    52.5

    +1.16%

  • NGG

    -0.4100

    83.01

    -0.49%

  • RELX

    0.4200

    31.34

    +1.34%

  • AZN

    2.7300

    188.41

    +1.45%

  • JRI

    0.2100

    12.79

    +1.64%

  • RYCEF

    0.3900

    18.39

    +2.12%

  • VOD

    0.0300

    13.89

    +0.22%

  • BTI

    0.2800

    62.76

    +0.45%

  • BP

    -0.5900

    37.13

    -1.59%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

L.Muratori--NZN